Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2012. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan transactions.
- Share Price: 1,482 pence per Ordinary share.
- ADR Price: $46.13 per ADR.
- Dividend Date: January 5, 2012.
Material Changes
On January 10, 2012, the Administrators of the Performance Share Plan notified the Company of an increase in notional interests for various directors and managers. This increase resulted from the notional re-investment of the dividend paid on January 5, 2012.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period. The notification complies with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the vesting schedule and conditions for the Performance Share Plan to understand future payout obligations.
- Confirm the total number of shares or ADRs held by key executives post-reinvestment.
- Review the full dividend declaration details from January 5, 2012, to contextualize the re-investment amounts.